Table 1.

Patient characteristics by the molecular subgroup

WNTa,bSHHGroup 3Group 4
Number of Patients (%)Number of Patients (%)Number of Patients (%)Number of Patients (%)P
Total patients3 (4)25 (31)21 (26)32 (39)
Age group, y<0.01c
 <30 (0)15 (60)5 (24)2 (6)
 3–60 (0)5 (20)6 (29)11 (34)
 6–102 (67)4 (16)6 (29)10 (31)
 >101 (33)1 (4)4 (19)9 (28)
Sex<0.05c
 Male0 (0)13 (52)14 (67)25 (78)
 Female3 (100)12 (48)7 (33)7 (22)
M Stage0.41c
 M03 (100)21 (84)14 (67)23 (72)
 M10 (0)1 (4)2 (10)0 (0)
 M20 (0)0 (0)1 (5)0 (0)
 M30 (0)3 (12)4 (19)9 (28)
Histology<0.001c
 Desmoplastic0 (0)13 (52)1 (5)2 (6)
 Classic3 (100)11 (44)12 (57)22 (69)
 Anaplastic0 (0)1 (4)8 (38)8 (25)
 Number of events0 (0)5 (20)7 (33)11 (34)d
 Number of deaths0 (0)3 (12)6 (29)9 (28)d
  • aThe molecular group based on TLDA analysis.

  • bTwo designated WNT based on presence of CTNNB1 mutation.

  • cOn the basis of the χ2 test.

  • dOn the basis of the Kaplan–Meier method and log-rank test.